Charge detection MS accelerates biotherapeutic analysis

Analysing today’s increasingly large and heterogeneous biotherapeutics remains a major challenge for drug developers, particularly in areas such as cell and gene therapy, mRNA, and complex protein assemblies.

Waters Corporation has introduced the Xevo™ Charge Detection Mass Spectrometer (CDMS) to address this gap, enabling direct, individual-particle mass measurement for biomolecules exceeding 150 MDa. The system allows accurate characterisation of protein complexes, nucleic acids, lipid nanoparticles, and viral vectors that are difficult or impossible to analyse using conventional techniques.

The Xevo CDMS can distinguish between empty, partial, full, and overfull viral vector capsids in less than 10 minutes per sample, while using up to 100-fold less material than existing methods. By removing the need for deconvolution or digestion, the approach delivers faster, more confident analysis across discovery, process development, and early manufacturing workflows.

“Advanced analytical tools are essential for understanding complex drug modalities earlier in development,” said Udit Batra, PhD, President and CEO of Waters Corporation. “The Xevo CDMS enables precise measurement of molecules that were previously beyond reach, supporting faster progress toward next-generation therapies.”

Powered by GxP-ready waters_connect™ software, the Xevo CDMS is available to order now.

More information online